NDRC Official Admits 80% Of China’s Imported Drugs More Pricey Than H.K., Korea, Taiwan
This article was originally published in PharmAsia News
Executive Summary
A senior pricing official of China’s National Development and Reform Commission (NDRC) admitted that of China’s over 300 stated-regulated imported drugs, 80% are more expensive than South Korea, Hong Kong and Taiwan, but 70% are cheaper than Europe, the U.S. and Japan.